All lobbying filings

THE MCMANUS GROUP

Lobbying for ARDELYX · BioPharma Company

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 3

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 6214
Kidney Care Access Protection Act

Lobbying activity 1

Medicare/Medicaid

Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment. H.R.6214 - Kidney Care Access Protection Act Issues related to Most Favored Nation Drug Pricing Reform

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.